Review
Open access
Sep 2026
Biomarkers in Clear Cell Renal Cell Carcinoma: From Biological Association to Clinical Decision-Making
Therapeutic options in renal cell carcinoma (RCC) have expanded rapidly, including adjuvant pembrolizumab, HIF-2α-directed therapy, and multiple effective first-line combinations for metastatic clear-cell RCC (ccRCC), yet treatment selection remains largely clinicopathologic. This review evaluates biomarkers at three c...
Hadi Al Etri, Lea Al Zoghby, Mohamad Sadek Zoghbi et al.
· Genes · 0 citations